Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:56 UTC |
---|
HMDB ID | HMDB0015328 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Captopril |
---|
Description | Captopril, also known as capoten or acepress, belongs to the class of organic compounds known as proline and derivatives. Proline and derivatives are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. Captopril is a drug which is used for the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). may be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). may improve survival in patients with left ventricular dysfunction following myocardial infarction. may be used to treat nephropathy, including diabetic nephropathy. . Captopril is an extremely weak basic (essentially neutral) compound (based on its pKa). In humans, captopril is involved in captopril action pathway. A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. |
---|
Structure | C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1 |
---|
Synonyms | Value | Source |
---|
(2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid | ChEBI | Acepress | ChEBI | Apopril | ChEBI | Capoten | ChEBI | Captolane | ChEBI | Captoprilum | ChEBI | Captopryl | ChEBI | Captoril | ChEBI | Cesplon | ChEBI | CP | ChEBI | D-2-Methyl-3-mercaptopropanoyl-L-proline | ChEBI | D-3-Mercapto-2-methylpropanoyl-L-proline | ChEBI | Dilabar | ChEBI | Garranil | ChEBI | Hypertil | ChEBI | L-Captopril | ChEBI | Lopirin | ChEBI | Tenosbon | ChEBI | Tensobon | ChEBI | Tensoprel | ChEBI | (2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylate | Generator | (2S)-1-[(2S)-2-Methyl-3-sulphanylpropanoyl]pyrrolidine-2-carboxylate | Generator | (2S)-1-[(2S)-2-Methyl-3-sulphanylpropanoyl]pyrrolidine-2-carboxylic acid | Generator | (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline | HMDB |
|
---|
Chemical Formula | C9H15NO3S |
---|
Average Molecular Weight | 217.285 |
---|
Monoisotopic Molecular Weight | 217.077264041 |
---|
IUPAC Name | (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid |
---|
Traditional Name | captopril |
---|
CAS Registry Number | 62571-86-2 |
---|
SMILES | C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O |
---|
InChI Identifier | InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1 |
---|
InChI Key | FAKRSMQSSFJEIM-RQJHMYQMSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as proline and derivatives. Proline and derivatives are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Proline and derivatives |
---|
Alternative Parents | |
---|
Substituents | - N-acyl-alpha-amino acid
- N-acyl-alpha amino acid or derivatives
- N-acyl-l-alpha-amino acid
- Proline or derivatives
- N-acylpyrrolidine
- Pyrrolidine carboxylic acid
- Pyrrolidine carboxylic acid or derivatives
- Pyrrolidine
- Tertiary carboxylic acid amide
- Carboxamide group
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Alkylthiol
- Azacycle
- Organoheterocyclic compound
- Organonitrogen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organic oxygen compound
- Organooxygen compound
- Organosulfur compound
- Carbonyl group
- Organic oxide
- Organic nitrogen compound
- Aliphatic heteromonocyclic compound
|
---|
Molecular Framework | Aliphatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 106 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 4.52 g/L | Not Available | LogP | 0.6 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | CBM | 142.5 | 30932474 |
|
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Captopril,1TMS,isomer #1 | C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C | 1879.3 | Semi standard non polar | 33892256 | Captopril,1TMS,isomer #2 | C[C@H](CS[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 1974.6 | Semi standard non polar | 33892256 | Captopril,2TMS,isomer #1 | C[C@H](CS[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C | 2006.2 | Semi standard non polar | 33892256 | Captopril,2TMS,isomer #1 | C[C@H](CS[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C | 2051.6 | Standard non polar | 33892256 | Captopril,2TMS,isomer #1 | C[C@H](CS[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C | 2429.3 | Standard polar | 33892256 | Captopril,1TBDMS,isomer #1 | C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 2128.0 | Semi standard non polar | 33892256 | Captopril,1TBDMS,isomer #2 | C[C@H](CS[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 2210.4 | Semi standard non polar | 33892256 | Captopril,2TBDMS,isomer #1 | C[C@H](CS[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 2469.1 | Semi standard non polar | 33892256 | Captopril,2TBDMS,isomer #1 | C[C@H](CS[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 2503.0 | Standard non polar | 33892256 | Captopril,2TBDMS,isomer #1 | C[C@H](CS[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 2596.0 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Captopril GC-MS (Non-derivatized) - 70eV, Positive | splash10-002f-9400000000-51d6dae57d8b305064ac | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Captopril GC-MS (1 TMS) - 70eV, Positive | splash10-00fr-9410000000-65f35f9df00d94abb290 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Captopril GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Captopril GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril LC-ESI-qTof , Positive-QTOF | splash10-014i-0940000000-26ddf220b67fb8dcdff0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril LC-ESI-QFT , negative-QTOF | splash10-001i-0910000000-8797427ebbfead8313f9 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril , positive-QTOF | splash10-014i-0940000000-26ddf220b67fb8dcdff0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril , positive-QTOF | splash10-01b9-8910000000-d831e8d48402a4c5fe73 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril LC-ESI-QFT , positive-QTOF | splash10-01b9-9720000000-8218e12ef8f7e988c312 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 10V, Positive-QTOF | splash10-014i-0490000000-368990ca74ad93e14251 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 10V, Positive-QTOF | splash10-014i-0290000000-1fecd0b4a33bc6afc4f2 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 20V, Positive-QTOF | splash10-01b9-0940000000-089a033b51be30f3a297 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 10V, Positive-QTOF | splash10-014i-3950000000-02525f49c5ae7c64e751 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 50V, Positive-QTOF | splash10-00di-9100000000-2d3dff49389d32966270 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 50V, Positive-QTOF | splash10-00di-9000000000-5fec50f211615a61cd58 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 30V, Positive-QTOF | splash10-00di-9200000000-955e87fa6bbc3b688dc5 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 30V, Positive-QTOF | splash10-00di-9300000000-12f0a42fb63fd9a341e4 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 30V, Positive-QTOF | splash10-00di-9100000000-8a3f39d9e1f9e0ddfa3a | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 35V, Positive-QTOF | splash10-01b9-9720000000-cc5d5a56e386ed3da5df | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 35V, Negative-QTOF | splash10-001i-0910000000-8797427ebbfead8313f9 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 50V, Positive-QTOF | splash10-014i-4920000000-abe7ab7a43bb4ab37f27 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 10V, Positive-QTOF | splash10-014i-0390000000-443943c884569fe9bdde | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Captopril 10V, Positive-QTOF | splash10-014i-2950000000-6310d54f5354a953ff47 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Captopril 10V, Positive-QTOF | splash10-014i-0890000000-6471cadb8251b2cde228 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Captopril 20V, Positive-QTOF | splash10-0uk9-3920000000-93e7eef38f7bf8d57f56 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Captopril 40V, Positive-QTOF | splash10-0udi-9400000000-f8b12a12ec76d0508922 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Captopril 10V, Negative-QTOF | splash10-00lr-1930000000-21d83329a778cc965f80 | 2016-08-04 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Captopril 20V, Negative-QTOF | splash10-00yr-2910000000-30e872740f7cb996700d | 2016-08-04 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Captopril 40V, Negative-QTOF | splash10-015c-9500000000-9c8558c81f9491de8c08 | 2016-08-04 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum |
|
---|
General References | - Atkinson AB, Robertson JI: Captopril in the treatment of clinical hypertension and cardiac failure. Lancet. 1979 Oct 20;2(8147):836-9. [PubMed:90928 ]
- Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Rothrock JW, Aster SD, Maycock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, Stone CA: A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280-3. [PubMed:6253826 ]
- Smith CG, Vane JR: The discovery of captopril. FASEB J. 2003 May;17(8):788-9. [PubMed:12724335 ]
|
---|